Read by QxMD icon Read

OPG AND peripheral arterial disease

Katarína Demková, Miriam Kozárová, Zuzana Malachovská, Martin Javorský, Ivan Tkáč
BACKGROUND: Osteoprotegerin plays a role in the development of several bone diseases. In addition, osteoprotegerin may contribute to the development of vascular disease. Little is known about the association between serum osteoprotegerin levels and the presence or severity of peripheral arterial disease (PAD). The aim of this study was to examine the association between serum osteoprotegerin levels and both the presence as well as the severity of lower extremity arterial disease in patients with type 2 diabetes (T2DM)...
February 2018: VASA. Zeitschrift Für Gefässkrankheiten
Yen-Cheng Chen, Bang-Gee Hsu, Ching-Chun Ho, Chung-Jen Lee, Ming-Che Lee
BACKGROUND: Osteoprotegerin (OPG) is a potential biomarker for severity and complications of cardiovascular diseases. Peripheral arterial disease (PAD) is associated with an increased risk of death in kidney transplantation (KT) patients. This prospective cross-sectional study evaluated the relationship between serum OPG and PAD in KT patients. METHODS: Seventy-four KT patients were enrolled for this PAD study. Fasting blood samples were obtained to measure serum OPG levels by using enzyme-linked immunosorbent assay kits...
2017: PeerJ
Hong-Mou Zhao, Jia-Yu Diao, Xiao-Jun Liang, Feng Zhang, Ding-Jun Hao
Diabetic neuropathic osteoarthropathy (DNOAP) is an uncommon, but with considerable morbidity and mortality rates, complication of diabetes. The real pathogenesis is still unclear. The two popular theories are the neuro-vascular theory and neuro-traumatic theory. Most theories and pathways focused on the uncontrolled inflammations that resulted in the final common pathway, receptor activator of nuclear factor κβ ligand (RANKL)/osteoprotegerin (OPG) axis, for the decreased bone density in DNOAP with an osteoclast and osteoblast imbalance...
October 2, 2017: Journal of Orthopaedic Surgery and Research
Silvia Giovannini, Giovanni Tinelli, Federico Biscetti, Giuseppe Straface, Flavia Angelini, Dario Pitocco, Luciana Mucci, Raffaele Landolfi, Andrea Flex
BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D...
August 8, 2017: Cardiovascular Diabetology
Elod Erno Nagy, Timea Varga-Fekete, Attila Puskas, Piroska Kelemen, Zoltan Brassai, Katalin Szekeres-Csiki, Timea Gombos, Maria Csilla Csanyi, Jolan Harsfalvi
BACKGROUND: Osteoprotegerin (OPG) and von Willebrand factor (VWF) form complex within endothelial cells and following secretion. The nature of blood group antigens strongly influences the levels of circulating VWF, but there is no available data concerning its ascendancy on OPG levels. We aimed to assess the relationship of AB0 blood groups with OPG, VWF levels (VWF: Ag) and collagen binding activity (VWF: CB) in peripheral arterial disease (PAD) patients. METHODS: Functional and laboratory parameters of 105 PAD patients and 109 controls were examined...
May 26, 2016: BMC Cardiovascular Disorders
Q Ge, C Ruan, P Gao, Y Ma, D Zhu, J Wang
OBJECTIVE: Monocytes/macrophages are believed to play roles in vascular calcification(VC). Here, we analyzed whether osteopontin(OPN) and osteoprotegerin(OPG) might exert effects by promoting macrophage polarization into an anti-inflammatory phenotype in the patients with hypertension(HT)-related VC.(Figure is included in full-text article.) DESIGN AND METHOD: : In this study, 412 HT patients with or without VC were identified by using artery electronic calculators tomography(fig 1)...
June 2015: Journal of Hypertension
Dimitrios Kapetanios, Christos Karkos, Ioakeim Giagtzidis, Konstantinos Papazoglou, Konstantinos Kiroplastis, Charalampos Spyridis
BACKGROUND: The aim of this study was to evaluate the association of the calcification regulators, osteopontin (OPN) and osteoprotegerin (OPG), which are involved in vascular calcification and atherosclerosis in patients with peripheral arterial disease (PAD). METHODS: A PubMed search of the English language literature was undertaken to identify articles that examine the role of the vascular calcification markers (OPN and OPG) in patients with PAD. The search retrieved 94 articles...
October 2016: International Angiology: a Journal of the International Union of Angiology
Patrick H Dessein, Raquel Lopez-Mejias, Begona Ubilla, Fernanda Genre, Alfonso Corrales, Jose L Hernandez, Ivan Ferraz-Amaro, Linda Tsang, Trinitario Pina, Javier Llorca, Ricardo Blanco, Carlos Gonzalez-Juanatey, Miguel A Gonzalez-Gay
OBJECTIVES: We examined the association of TNF-related apoptosis-inducing ligand (TRAIL) concentrations with cardiovascular disease (CVD) in rheumatoid arthritis (RA) and, since osteoprotegerin (OPG) can act as a decoy receptor for TRAIL, whether TRAIL concentrations impact on the OPG level-atherosclerotic CVD relation that was recently documented in the present cohort. METHODS: TRAIL concentrations were assessed by ELISA in 151 RA patients of which 75 (49.7%) had CVD comprising ischaemic heart disease (n=27), cerebrovascular accident (n=26), peripheral artery disease (n=9) or/and heart failure (HF) (n=27), and 62 controls...
July 2015: Clinical and Experimental Rheumatology
Raquel López-Mejias, Begoña Ubilla, Fernanda Genre, Alfonso Corrales, José L Hernández, Ivan Ferraz-Amaro, Linda Tsang, Javier Llorca, Ricardo Blanco, Carlos González-Juanatey, Miguel A Gonzalez-Gay, Patrick H Dessein
OBJECTIVE: We determined whether osteoprotegerin (OPG) concentrations are associated with established cardiovascular disease (CVD) among patients with rheumatoid arthritis (RA). METHODS: OPG concentrations were measured by ELISA in 151 patients with RA (54 with CVD) and 62 age-matched control subjects without CVD. Established CVD was composed of documented ischemic heart disease, cerebrovascular disease, and peripheral artery disease. RESULTS: In patients with RA, age, body mass index (BMI), rheumatoid factor (RF) positivity, anticyclic citrullinated peptide (anti-CCP) antibody positivity, and joint erosion status were associated with OPG concentrations [partial R (p) = 0...
January 2015: Journal of Rheumatology
Federico Biscetti, Carlo Filippo Porreca, Flavio Bertucci, Giuseppe Straface, Angelo Santoliquido, Paolo Tondi, Flavia Angelini, Dario Pitocco, Luca Santoro, Antonio Gasbarrini, Raffaele Landolfi, Andrea Flex
AIMS: Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis factor receptor family and plays a role in atherosclerosis. OPG has been hypothesized to modulate vascular functions; however, its role in mediating atherosclerosis is controversial. Epidemiological data in patients with cardiovascular disease (CVD) indicate that OPG serum levels are associated with several inflammatory markers, myocardial infarction events, and calcium scores, suggesting that OPG may be causative for CVD...
December 2014: Acta Diabetologica
Olivier Bourron, Carole Elodie Aubert, Sophie Liabeuf, Philippe Cluzel, Frédérique Lajat-Kiss, Michel Dadon, Michel Komajda, Romuald Mentaverri, Michel Brazier, Antoine Pierucci, Florence Morel, Sophie Jacqueminet, Ziad A Massy, Agnès Hartemann
CONTEXT: Calcification of the arterial wall in diabetes contributes to the arterial occlusive process occurring below the knee. The osteoprotegerin (OPG)/receptor activator of nuclear factor κB ligand (RANKL) system is suspected to be involved in the calcification process. OBJECTIVE: The aim of the study was to investigate whether there is a link between arterial calcification in type 2 diabetes and 1) conventional cardiovascular risk factors, 2) serum RANKL and OPG levels, and 3) neuropathy...
November 2014: Journal of Clinical Endocrinology and Metabolism
Cesar Varela, Francisco Acin, Ignacio Lopez de Maturana, Joaquin de Haro, Silvia Bleda, Belky Paz, Leticia Esparza
BACKGROUND: Objective performance goals (OPGs) are a set of standardized end points generated from well documented historical controls against which new therapeutic procedures may be compared in single-arm studies. Recently, the Society for Vascular Surgery suggested a set of OPGs designed from vein bypass controls that could be used to evaluate the safety and efficacy of endovascular devices applied to critical limb ischemia through a noninferiority analysis. Our aim is to analyze the results of infrapopliteal endovascular procedures performed in patients with critical limb ischemia according to these OPG end points...
February 2014: Annals of Vascular Surgery
Agnieszka Czyzewska-Buczyńska, Natalia Zuk, Sebastian Bałasz, Wojciech Witkiewicz
Abdominal Aortic Aneurysm (AAA) is multifactorial disease with unknown ethiology. Among the theories on the pathogenesis of AAA are some ge. netic factors, infections, disorders in connective tissue (collagenosis), arteriosclerosis, inflammation, incorrect immune response (autoimmunity). It was discovered that crucial for AAA development is intense inflammatory reaction combined with high proteolytic activity. Recent evidence confirmed the association between osteopontin (OPN) and osteoprotegerin (OPG) levels and cardiovascular diseases and arterio...
2013: Przegla̧d Lekarski
Daniel Gordin, Aino Soro-Paavonen, Merlin C Thomas, Valma Harjutsalo, Markku Saraheimo, Mette Bjerre, Carol Forsblom, Allan Flyvbjerg, Per-Henrik Groop
OBJECTIVE: Osteoprotegerin (OPG) is involved in the process of vascular calcification. We investigated whether OPG is associated with the development and progression of diabetes complications in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Serum OPG was measured in 1,939 adults with T1D participating in the Finnish Diabetic Nephropathy (FinnDiane) Study. Patients with end-stage renal disease (dialysis or transplantation) at baseline were excluded from analysis...
July 2013: Diabetes Care
Susanne Elisabeth Hosbond, Tina Svenstrup Poulsen, Axel Cosmus Pyndt Diederichsen, Mads Nybo, Lars Melholt Rasmussen, Hans Mickley
OBJECTIVE: Osteoprotegerin (OPG) may be involved in development of atherosclerosis. To evaluate plasma concentrations of OPG in individuals with stable coronary artery disease (CAD), acute coronary syndrome (ACS), peripheral artery disease (PAD), and cerebrovascular disease (CBVD) a systematic literature review was performed. DESIGN AND METHODS: Studies investigating OPG concentrations in stable CAD, ACS, PAD, and CBVD were extracted from PubMed and the Cochrane Library, retrieving 280 articles...
August 2012: Scandinavian Cardiovascular Journal: SCJ
P Rozas Moreno, R Reyes García, A García-Martín, M Varsavsky, J A García-Salcedo, M Muñoz-Torres
BACKGROUND: The role of osteoprotegerin (OPG) as a marker of cardiovascular disease (CVD) in Type 2 diabetes (T2DM) is not well established. Moreover, the relationship between OPG, osteoporosis, and vertebral fractures in T2DM remains to be elucidated. AIM: To determine the role of serum OPG in the prediction of CVD and bone disease in T2DM males. SUBJECTS AND METHODS: Cross-sectional study with 68 males, 43 with T2DM and 25 subjects without diabetes...
January 2013: Journal of Endocrinological Investigation
Dhruv K Singh, Peter Winocour, Bev Summerhayes, Sunil Kaniyur, Adie Viljoen, G Sivakumar, Ken Farrington
AIMS: To determine predictors of prevalence and progression of peripheral vascular calcification (VC) in type 2 diabetes (DM) subjects with preserved kidney function. METHODS: Fifty-eight subjects (age 63 ± 11.6 years) with type 2 DM and serum creatinine <125 μmol/l were studied. A CT scan of femoral, posterior tibial and dorsalis pedis arteries was carried out at baseline and at one year. Serum osteoprotegerin (OPG) and RANKL were measured along with routine biochemistry...
July 2012: Diabetes Research and Clinical Practice
Mikael K Poulsen, Mads Nybo, Jordi Dahl, Susanne Hosbond, Tina S Poulsen, Allan Johansen, Poul F Høilund-Carlsen, Henning Beck-Nielsen, Lars M Rasmussen, Jan E Henriksen
BACKGROUND: Cardiovascular disease (CVD) is frequent in type 2 diabetes mellitus patients due to accelerated atherosclerosis. Plasma osteoprotegerin (OPG) has evolved as a biomarker for CVD. We examined the relationship between plasma OPG levels and different CVD manifestations in type 2 diabetes. METHODS: Type 2 diabetes patients without known CVD referred consecutively to a diabetes clinic for the first time (n = 305, aged: 58.6 ± 11.3 years, diabetes duration: 4...
August 12, 2011: Cardiovascular Diabetology
Shripad N Pal, Paula Clancy, Jonathan Golledge
BACKGROUND: To investigate the association between aortic calcification, concentrations of stem-cell-mobilizing cytokines and osteocalcin-positive mononuclear cells in a mouse model and patients with peripheral artery disease. METHODS AND RESULTS: We estimated the concentration of the stem-cell-mobilizing cytokines stromal cell-derived factor α (SDF-1α), granulocyte colony stimulating factor and stem cell factor in a mouse model of aortic calcification developed in osteoprotegerin-deficient (OPG(-/-)) mice, as well as in patient plasma samples...
2011: Circulation Journal: Official Journal of the Japanese Circulation Society
Eoin P O'Sullivan, David T Ashley, Colin Davenport, James Kelly, Niamh Devlin, Rachel Crowley, Austin L Leahy, Cathal J Kelly, Amar Agha, Christopher J Thompson, Donal J O'Gorman, Patricia Fitzgerald, Diarmuid Smith
INTRODUCTION: Peripheral arterial disease (PAD) and type 2 diabetes mellitus (DM) are both associated with excessive vascular calcification and elevated levels of inflammatory markers IL-6 and hsCRP. The recently identified Osteoprotegerin(OPG)/RANKL/TRAIL pathway has been implicated in vascular calcification, but data on levels in PAD and effect of co-existent DM are lacking. MATERIALS AND METHODS: 4 groups of patients were recruited - 26 with PAD and DM, 35 with DM alone, 22 with PAD alone, and 21 healthy individuals...
December 2010: Thrombosis Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"